SERIAL ESR1 MUTATION MONITORING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Market Segmentation

• Testing Technology Insights (Revenue, USD Mn, 2021 - 2033)

  • Next-Generation Sequencing (NGS)
  • PCR-Based Assays
  • Digital Droplet PCR (ddPCR)

• Sample Type Insights (Revenue, USD Mn, 2021 - 2033)

  • Plasma
  • Serum
  • Other Blood-Derived Samples

• Monitoring Approach Insights (Revenue, USD Mn, 2021 - 2033)

  • Baseline ESR1 Mutation Testing
  • Serial ctDNA Monitoring During Treatment
  • Testing at Disease Progression

• Application Insights (Revenue, USD Mn, 2021 - 2033)

  • Detection of Endocrine Therapy Resistance
  • Treatment Selection and Modification
  • Monitoring of Emerging ESR1 Mutations

• End User Insights (Revenue, USD Mn, 2021 - 2033)

  • Hospitals and Oncology Clinics
  • Diagnostic and Reference Laboratories
  • Cancer Research and Academic Institutes
  • Others

• Regional Insights (Revenue, USD Mn, 2021 - 2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa

• Key Players Insights

  • Guardant Health, Inc.
  • Foundation Medicine, Inc.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • NeoGenomics Laboratories, Inc.
  • Roche Diagnostics
  • Sysmex Corporation
  • Tempus AI, Inc.
  • GENCURIX, Inc.